Related Experiment Video
Updated: May 26, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus
Borja Del Carmelo Gracia Tello1, José Miguel García-Bruñén1, Luis Corredor2
1Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Frontiers in Immunology
|May 25, 2026
Summary
Elevated Interleukin-6 (IL-6) levels predict near-term disease flares in Systemic Lupus Erythematosus (SLE). This finding may help identify patients at risk for reactivation and guide treatment decisions.
Area of Science:
- Rheumatology
- Immunology
- Biomarker Discovery
Background:
- Systemic Lupus Erythematosus (SLE) is marked by unpredictable flares causing organ damage.
- Current biomarkers lack the ability to reliably predict near-term SLE reactivation.
- The predictive value of Interleukin-6 (IL-6) for SLE flares is uncertain.
Purpose of the Study:
- To prospectively evaluate Interleukin-6 (IL-6) as a predictive biomarker for disease reactivation in Systemic Lupus Erythematosus (SLE).
- To compare the discriminative performance of IL-6 against established SLE biomarkers.
Main Methods:
- A prospective, longitudinal study of 188 adult SLE patients from 2017-2023.
- Serum IL-6 levels were measured, with a cutoff of 5 pg/mL used for categorization.
- Disease activity (SLEDAI-2K >4) and organ-specific manifestations were assessed; associations were analyzed using log-rank tests and ROC analyses.
Main Results:
- 48% of patients exhibited IL-6 levels >5 pg/mL during follow-up.
- Elevated IL-6 ( >5 pg/mL) was associated with a shorter time to subsequent disease flares (median 10 months sooner for SLEDAI-2K >4).
- IL-6 predicted specific manifestations including arthritis, nephritis, serositis, and hematologic issues, outperforming anti-dsDNA, C3, and C4.
Conclusions:
- Elevated serum IL-6 levels are significantly associated with short-term disease reactivation in SLE patients.
- IL-6 shows promise as a complementary biomarker for longitudinal disease assessment in SLE.
- These findings support the use of IL-6 monitoring for predicting SLE flares.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...